High-dose recombinant interferon a-2B
Phase 3Small molecule
Innovent Biologics (Suzhou) Co. Ltd.High-dose recombinant interferon a-2B is one of 57 small molecule programs targeting Melanoma. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Lenvima
EisaiPhase 3
Actimmune
HHorizon Therapeutics Ireland DAC
Phase 3
KIMMTRAK
IImmunocore Ltd
Phase 3
Fotemustine
RochePhase 3
Interferon Alfa
PfizerPhase 3
Histamine Dihydrochloride
MMaxim Pharmaceuticals
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
High-dose recombinant interferon a-2B
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details